portfolio reprioritization
Takeda to Cut 137 Staffers After Exiting Cell Therapy Research
Takeda; layoffs; cell therapy exit; biotech industry; restructuring; Massachusetts R&D; strategic portfolio reprioritization; pipeline shake-up
Actionable Insights Powered by AI
Takeda; layoffs; cell therapy exit; biotech industry; restructuring; Massachusetts R&D; strategic portfolio reprioritization; pipeline shake-up